Cargando…
Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
SGLT-2 inhibitors (SGLT-2Is) have significantly improved cardio-renal outcomes and are preferred agents in people with cardiovascular diseases, heart failure, and diabetic kidney disease. Similarly, GLP-1 receptor agonists (GLP-1RAs) have significantly improved atherosclerotic cardiovascular outcome...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210541/ https://www.ncbi.nlm.nih.gov/pubmed/35800411 http://dx.doi.org/10.4239/wjd.v13.i6.466 |
_version_ | 1784730178821292032 |
---|---|
author | Singh, Awadhesh Kumar Singh, Ritu |
author_facet | Singh, Awadhesh Kumar Singh, Ritu |
author_sort | Singh, Awadhesh Kumar |
collection | PubMed |
description | SGLT-2 inhibitors (SGLT-2Is) have significantly improved cardio-renal outcomes and are preferred agents in people with cardiovascular diseases, heart failure, and diabetic kidney disease. Similarly, GLP-1 receptor agonists (GLP-1RAs) have significantly improved atherosclerotic cardiovascular outcomes. To this end, DPP-4 inhibitors (DPP-4Is) are cardiac-neutral drugs. While long-acting GLP-1RAs have shown a favorable HbA1c lowering compared to DPP-4Is, there is no clinically meaningful HbA1c lowering difference between SGLT-2Is vs DPP-4Is. Moreover, the glucose-lowering potential of SGLT-2Is gets compromised with a progressive decline in renal functions, unlike DPP-4Is. Furthermore, the HbA1c lowering potential of DPP-4Is is favorable in people with T2DM having a modest baseline HbA1c (8.0%-8.5%) compared with SGLT-2Is which lowers HbA1c larger in a background of higher baseline HbA1c (> 8.5%-9.0%). These findings suggest that the role of DPP-4Is in the management of type 2 diabetes mellitus cannot be completely ignored even in the era of SGLT-2Is. |
format | Online Article Text |
id | pubmed-9210541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-92105412022-07-06 Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors Singh, Awadhesh Kumar Singh, Ritu World J Diabetes Letter to the Editor SGLT-2 inhibitors (SGLT-2Is) have significantly improved cardio-renal outcomes and are preferred agents in people with cardiovascular diseases, heart failure, and diabetic kidney disease. Similarly, GLP-1 receptor agonists (GLP-1RAs) have significantly improved atherosclerotic cardiovascular outcomes. To this end, DPP-4 inhibitors (DPP-4Is) are cardiac-neutral drugs. While long-acting GLP-1RAs have shown a favorable HbA1c lowering compared to DPP-4Is, there is no clinically meaningful HbA1c lowering difference between SGLT-2Is vs DPP-4Is. Moreover, the glucose-lowering potential of SGLT-2Is gets compromised with a progressive decline in renal functions, unlike DPP-4Is. Furthermore, the HbA1c lowering potential of DPP-4Is is favorable in people with T2DM having a modest baseline HbA1c (8.0%-8.5%) compared with SGLT-2Is which lowers HbA1c larger in a background of higher baseline HbA1c (> 8.5%-9.0%). These findings suggest that the role of DPP-4Is in the management of type 2 diabetes mellitus cannot be completely ignored even in the era of SGLT-2Is. Baishideng Publishing Group Inc 2022-06-15 2022-06-15 /pmc/articles/PMC9210541/ /pubmed/35800411 http://dx.doi.org/10.4239/wjd.v13.i6.466 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Letter to the Editor Singh, Awadhesh Kumar Singh, Ritu Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors |
title | Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors |
title_full | Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors |
title_fullStr | Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors |
title_full_unstemmed | Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors |
title_short | Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors |
title_sort | relook at dpp-4 inhibitors in the era of sglt-2 inhibitors |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210541/ https://www.ncbi.nlm.nih.gov/pubmed/35800411 http://dx.doi.org/10.4239/wjd.v13.i6.466 |
work_keys_str_mv | AT singhawadheshkumar relookatdpp4inhibitorsintheeraofsglt2inhibitors AT singhritu relookatdpp4inhibitorsintheeraofsglt2inhibitors |